Anti-RAGE Monoclonal for Research (Technology RFT-432b)

Generate a PDF of this technology.

Generate PDF

Invention Summary


Scientists at NDSU have developed a monoclonal antibody that inhibits activation of the receptor for advanced glycation end products (RAGE) by blocking the V-domain. The V-domain binds multiple ligands that elicit sustained inflammation associated with diabetes, cancer, Alzheimer’s, multiple sclerosis, and other diseases. As a result, this monoclonal has value in research related to a wide variety of diseases. This antibody is available via non-exclusive license for research use only.  Illustration and antibody specification figures are shown below.


Patent Status

The antibody has been non-exclusively licensed to multiple licensees for research purposes.


Saurabhi Satam, Business Development and Licensing Associate


RFT, 432, RFT432

Inquire about this technology >